Ramaswamy Govindan

Ramaswamy Govindan, MD

Top Doctors®

Specializes In
  • Medical Oncology
Languages Spoken
  • English

Appointments

Sees Patients For

Esophageal, thoracic and lung cancer

Hospital Affiliations

  • Barnes-Jewish Hospital

Locations

Experience

Board Certifications

  • Hematology
  • Internal Medicine
  • Medical Oncology

Academic Title(s)

Professor, Medicine
Division of Medical Oncology

Publications & Research

Search PubMed for publications »

Education

Fellowship

Hematology - Oncology at Washington University School of Medicine, St. Louis, MO

Residency

Internal Medicine at Michael Reese Hospital and Medical Center, Chicago, IL

Residency

Internal Medicine at JIPMER, India

Medical Degree

1987 University of Madras, Madras, India

B.S.

1980 SIR. MCTM Higher Secondary School, Madras, India

Financial Disclosures
  • PrecisCa
    • Speaker Fees: $20,000 - $39,999
    • Reporting Date: 05/01/2022

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.